PM-Scl antibody positive systemic sclerosis associated with inclusion-body myositis;PM-Scl-antikörper positive systemische sklerodermie assoziiert mit einschlusskörper-myositis

Zeitschrift fur Rheumatologie

Volumn 64, Issue 7, 2005, Pages 499-502

  Kim, S ^a   Genth, E ^b   Krieg, T ^a   Hunzelmann, N ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b Rheumaklinik   (Germany)

Author keywords

Dermatomyositis; Inclusion body myositis; Overlap syndrome; PM Scl antibody; Systemic sclerosis

Indexed keywords

ANTIBODY;

AGED; ARTICLE; CASE REPORT; CELL INCLUSION; DERMATOMYOSITIS; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MYOPATHY; MYOSITIS; POLYMYOSITIS; SYSTEMIC SCLEROSIS;

AGED; AUTOANTIGENS; BIOLOGICAL MARKERS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MYOSITIS, INCLUSION BODY; SCLERODERMA, SYSTEMIC;

EID: 27144467424     PISSN: 03401855     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00393-005-0664-1     Document Type: Article

References (28)

1. Barohn RJ, Amato AA, Sahenk Z, Kissel JT, Mendell JR (1995) Inclusion body myositis: Explanation for poor response to immunosuppressive therapy. Neurology 45:1302-1304
2. Barohn RJ, Amato AA (2000) Inclusion body myosits. Curr Treat Options Neurol 2:7-12
3. Brouwer R, Hengstmann GJD, Vree Egbert W et al (2001) Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 60:116-123
4. Calabrese LH, Mitsumoto H, Chou SM (1987) Inclusion body myositis presenting as treatment-resistant polymyositis. Arthritis Rheum 30:397-403
5. Cherin P (1999) Treatment of inclusion body myositis. Curr Opin Rheumatol 11:436-461
6. Dalakas MC, Sonies B, Dambrosia J, Sekul E (1997) Treatment of inclusion body myositis with IVIg. Neurology 48:712-716
7. Dalakas MC (1991) Polymyositis, dermatomyositis, and inclusion body myositis. N Engl J Med 21:1487-1498
8. Danon MJ, Reyes MG, Perurena OH, Masdeu JC, Manaligod JR (1982) Inclusion body myositis a corticosteroid-resistant idiopathic inflammatory myopathy. Arch Neurol 39:760-764
9. Genth E, Mierau R (1995) Diagnostische Bedeutung Sklerodermie- und Myositis-assoziierter Autoantikörper. Z Rheumatol 54:39-49
10. Genth E (2000) Entzündliche Muskelkrankheiten aus internistischer Sicht. Internist 41:445-454
11. Hengstmann GJD, van Engelen BGM, Badrising UA, van den Hoogen FHJ, van Venrooij WJ (1998) Presence of the anti-Jo-1 autoantibody excludes inclusion body myositis. Ann Neurol 44:423
12. Jablonska S, Blaszczyk M (1999) Scleroderma overlap syndromes. Rheuma Derm 45:85-92
13. Koffman BM, Rugiero M, Dalakas MC (1998) Immune mediated conditions and antibodies associated with sporadic inclusion body myositis. Muscle Nerve 21:115-117
14. Leff RL, Miller FW, Hicks J, Fraser DD, Plotz PH (1993) The treatment of inclusion body myositis: A retrospective and a randomized, propective trial of immunosuppressive therapy. Medicine 72:225-235
15. Lotz BP, Engel AG, Nishino H, Stevens JC (1989) Inclusion body myositis. Observations in 40 patients. Brain 112:727-747
16. Marguerie C, Bunn CC, Copier J, Bernstein RM, Gilroy JM, Black CM, So AK, Walport MJ (1992) The clinical and immunogenetic features of patients with auto antibodies to the nuclear antigen PM-Scl. Medicine (Baltimore) 71:327-336
17. Mendell JR, Sahenk Z, Gales T, Paul Z (1991) Amyloid filaments in inclusion body myositis: novel findings provide insight into nature of filaments. Arch Neurol 48:1229-1234
18. nd edition, Mc Graw-Hill Inc, pp 1384-1398
19. Mimori T (1996) Structures targeted by the immune system in myositis. Curr Opin Rheumatol 8:521-527
20. Mowzoon N, Sussman A, Bradley WG (2001) Mycophenolate (Cellcept) treatment of myastenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis. J Neurol Sci 185:119-122
21. Oddis CV, Okano Y, Rudert WA, Trucco M, Dusaquesnoy RJ, Medsger Ta Jr (1992) Serum autoantibody to the nuclear autoantigen PM-Scl: clinical and immunogenic associations. Arthritis Rheum 35:1211-1217
22. Reimer G, Scheer U, Peters JM, Tan EM (1986) Immunolocalisation and partial characterization of a nuclear autoantigen (PM-Scl) associated with polymyositis/scleroderma overlap syndrome. J Immunol 137:3802-3808
23. Richter Cohen M, Sulaiman AR, Garanics JC, Wortman RL (1989) Clinical heterogeneity and treatment response in inclusion body myositis. Arthritis Rheum 32:734-740
24. Schlesinger I, Soffer D, Lossos A, Meiner Z, Argov Z (1996) Inclusion body myositis: atypical clinical presentation. Eur Neurol 36:89-93
25. Sekul EA, Dalakas MC (1993) Inclusion body myositis: New concepts. Sem Neurol 13:256-263
26. Selva-O'Callaghan A, Mijares-Boeckh-Behrens T, Labrador-Horillos M, Soalns-Laque R, Ma Grau-Junyent J, Vilardell-Tarres M (2003) Anti-PM-Scl antibodies in a patient with inclusion body myositis. Rheumatology (Oxford) 42:1016-1018
27. Vogel H (1998) Inclusion body myositis - a review. Adv Anat Pathol 5:164-169
28. Grogan PM, Katz JS (2004) Inflammatory myopathies. Curr Treat Options Neurol 6:155-161